8,083.80-170.0
Stock Analysis, IPO, Mutual Funds, Bonds & More

Granules India gets USFDA nod for pain relief drug

The approved product is bioequivalent to the reference listed drug product (RLD), Tylenol tablets, extended release.

PTI|
Last Updated: Apr 18, 2019, 03.53 PM IST
0Comments
Agencies
Granules-India
Acetaminophen 650 mg extended release tablets are used primarily for temporary pain management. (Representative image)
Drug firm Granules India Thursday said it has received approval from the US health regulator for Acetaminophen tablets, used for temporary pain relief.

The approved product is bioequivalent to the reference listed drug product (RLD), Tylenol tablets, extended release.

The US Food and Drug Administration (USFDA) has approved its abbreviated new drug application (ANDA) for Acetaminophen 650 mg tablets, extended release, Granules said in a BSE filing.

Acetaminophen 650 mg extended release tablets are used primarily for temporary pain management.

"The addition of Acetaminophen 650mg, extended release tablets to our OTC portfolio leverages several components of our value proposition," Granules India Chairman and Managing Director Krishna Prasad Chigurupati said.

Shares of Granules India were trading 1.01 per cent lower at Rs 112.80 apiece on BSE.

Also Read

Sun Pharma drops 3% as USFDA initiates action against Halol facility

Cipla gets USFDA nod for generic acid reflux drug

USFDA inspects Alembic Pharma's facility in Karkhadi, Gujarat

Cipla announces closure of USFDA inspection at Patalganga facility

Biocon gets EIR from USFDA for manufacturing facility in Bengaluru

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service